These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 34129749)

  • 21. Safety of BNT162b2 mRNA COVID-19 vaccine in patients with mast cell disorders.
    Rosman Y; Lavi N; Meir-Shafrir K; Lachover-Roth I; Cohen-Engler A; Mekori YA; Confino-Cohen R
    J Allergy Clin Immunol Pract; 2021 Sep; 9(9):3487-3489. PubMed ID: 34224924
    [No Abstract]   [Full Text] [Related]  

  • 22. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
    Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
    Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 mRNA vaccine-associated fixed drug eruption.
    Mintoff D; Pisani D; Betts A; Scerri L
    J Eur Acad Dermatol Venereol; 2021 Sep; 35(9):e560-e563. PubMed ID: 34036651
    [No Abstract]   [Full Text] [Related]  

  • 24. Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis.
    Ducloux D; Colladant M; Chabannes M; Yannaraki M; Courivaud C
    Kidney Int; 2021 Sep; 100(3):702-704. PubMed ID: 34216675
    [No Abstract]   [Full Text] [Related]  

  • 25. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons.
    Sun H
    N Engl J Med; 2021 Oct; 385(16):1535-1536. PubMed ID: 34496197
    [No Abstract]   [Full Text] [Related]  

  • 27. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS).
    Welsh KJ; Baumblatt J; Chege W; Goud R; Nair N
    Vaccine; 2021 Jun; 39(25):3329-3332. PubMed ID: 34006408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. "COVID Arm": Very delayed large injection site reactions to mRNA COVID-19 vaccines.
    Ramos CL; Kelso JM
    J Allergy Clin Immunol Pract; 2021 Jun; 9(6):2480-2481. PubMed ID: 33864927
    [No Abstract]   [Full Text] [Related]  

  • 29. Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine".
    Schwotzer N; Kissling S; Fakhouri F
    Kidney Int; 2021 Aug; 100(2):458-459. PubMed ID: 34052236
    [No Abstract]   [Full Text] [Related]  

  • 30. On Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. Reply.
    Meaney-Delman DM; Ellington SR; Shimabukuro TT
    N Engl J Med; 2021 Oct; 385(16):1536. PubMed ID: 34496198
    [No Abstract]   [Full Text] [Related]  

  • 31. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered
    Elia U; Ramishetti S; Rosenfeld R; Dammes N; Bar-Haim E; Naidu GS; Makdasi E; Yahalom-Ronen Y; Tamir H; Paran N; Cohen O; Peer D
    ACS Nano; 2021 Jun; 15(6):9627-9637. PubMed ID: 33480671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralizing SARS-CoV-2 antibody response in dialysis patients after the first dose of the BNT162b2 mRNA COVID-19 vaccine: the war is far from being won.
    Torreggiani M; Blanchi S; Fois A; Fessi H; Piccoli GB
    Kidney Int; 2021 Jun; 99(6):1494-1496. PubMed ID: 33887320
    [No Abstract]   [Full Text] [Related]  

  • 33. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 ≥14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC28. PubMed ID: 33646836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A skin reaction with rust-like discolouration to mRNA COVID-19 vaccine.
    Pasternack R; Pohjavaara S
    J Eur Acad Dermatol Venereol; 2021 Nov; 35(11):e737-e738. PubMed ID: 34310755
    [No Abstract]   [Full Text] [Related]  

  • 36. Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021.
    Mazagatos C; Monge S; Olmedo C; Vega L; Gallego P; Martín-Merino E; Sierra MJ; Limia A; Larrauri A; ;
    Euro Surveill; 2021 Jun; 26(24):. PubMed ID: 34142647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working.
    Navar AM; McNally E; Yancy CW; O'Gara PT; Bonow RO
    JAMA Cardiol; 2021 Oct; 6(10):1117-1118. PubMed ID: 34185044
    [No Abstract]   [Full Text] [Related]  

  • 38. A New Vaccine to Battle Covid-19.
    Haynes BF
    N Engl J Med; 2021 Feb; 384(5):470-471. PubMed ID: 33378607
    [No Abstract]   [Full Text] [Related]  

  • 39. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.
    Rama TA; Moreira A; Castells M
    J Allergy Clin Immunol; 2021 Mar; 147(3):877-878. PubMed ID: 33485650
    [No Abstract]   [Full Text] [Related]  

  • 40. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients.
    Palich R; Veyri M; Marot S; Vozy A; Gligorov J; Maingon P; Marcelin AG; Spano JP
    Ann Oncol; 2021 Aug; 32(8):1051-1053. PubMed ID: 33932501
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.